CIITA Antikörper (Internal Region)
CIITA
Reaktivität: Human, Maus, Ratte
WB, ELISA
Wirt: Kaninchen
Polyclonal
unconjugated
Produktnummer ABIN1575655
-
-
Target
Alle CIITA Antikörper anzeigen
-
CIITA
(Class II, Major Histocompatibility Complex, Transactivator (CIITA))
-
Bindungsspezifität
-
Internal Region
-
Reaktivität
-
Human, Maus, Ratte
-
Wirt
-
Kaninchen
-
Klonalität
-
Polyklonal
-
Konjugat
-
Dieser CIITA Antikörper ist unkonjugiert
-
Applikation
-
Western Blotting (WB), ELISA
-
Spezifität
-
CIITA antibody detects endogenous levels of total CIITA protein.
-
Aufreinigung
-
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
-
Immunogen
-
The antiserum was produced against synthesized peptide derived from internal of human CIITA.
-
Top Product
-
Discover our top product CIITA Primärantikörper
-
-
-
Applikationshinweise
-
Optimal working dilution should be determined by the investigator.
-
Beschränkungen
-
Nur für Forschungszwecke einsetzbar
-
-
Konzentration
-
1 mg/mL
-
Buffer
-
Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.
-
Lagerung
-
-20 °C
-
Informationen zur Lagerung
-
Store at -20°C / 1 year
-
Haltbarkeit
-
12 months
-
-
Target
-
CIITA
(Class II, Major Histocompatibility Complex, Transactivator (CIITA))
-
Andere Bezeichnung
-
CIITA (CIITA Produkte)
-
Synonyme
-
CIITA antikoerper, C2ta antikoerper, EG669998 antikoerper, Gm9475 antikoerper, C2TA antikoerper, CIITAIV antikoerper, MHC2TA antikoerper, NLRA antikoerper, Mhc2ta antikoerper, class II, major histocompatibility complex, transactivator antikoerper, class II major histocompatibility complex transactivator antikoerper, MHC class II transactivator antikoerper, class II transactivator antikoerper, CIITA antikoerper, LOC710761 antikoerper, ciita antikoerper, LOC100443575 antikoerper, Ciita antikoerper, LOC100736732 antikoerper
-
Hintergrund
-
MHC class II transactivator, CIITA, CIITA, MHC2TA
-
UniProt
-
P33076
-
Pathways
-
Cancer Immune Checkpoints
-